XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash flows from operating activities:    
Net income (loss) $ (7,228,011) $ (234,007)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization expense 1,974,194 1,785,057
Deferred tax expense 4,293,963 662,689
Share-based compensation 849,198 623,504
Excess tax (benefit) expense derived from exercise of stock options (91,109) 907,270
Noncash interest expense 60,708 61,224
Noncash investment gains (48,084) (69,140)
Net changes in assets and liabilities affecting operating activities:    
Accounts receivable 124,748 (595,180)
Inventories (485,739) (713,084)
Other current assets and other assets (428,176) (1,241,372)
Accounts payable and other current liabilities 640,453 (1,705,007)
Other long-term liabilities 239,703 267,730
Net cash used in operating activities (98,152) (250,316)
Cash flows from investing activities:    
Additions to property and equipment (172,899) (98,275)
Purchases of marketable securities (2,029,414) (3,643,894)
Proceeds from sale of marketable securities 9,644,592 3,676,745
Additions to intangible assets (841,647) (1,554,410)
Net cash provided by (used in) investing activities 6,600,632 (1,619,834)
Cash flows from financing activities:    
Net borrowings on line of credit 3,900,000 2,000,000
Excess tax expense derived from exercise of stock options 0 (907,270)
Repurchase of common shares (2,893,857) (1,879,395)
Net cash provided by (used in) financing activities 1,006,143 (786,665)
Net increase (decrease) in cash and cash equivalents 7,508,623 (2,656,815)
Cash and cash equivalents at beginning of period 34,510,330 38,203,059
Cash and cash equivalents at end of period $ 42,018,953 $ 35,546,244